Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 20, 2016 09:00 ET | Source: Trifacta

Trifacta v4 Extends Enterprise Data Wrangling to Any User, Any Data, Any Cloud

SAN FRANCISCO, CA--(Marketwired - Sep 20, 2016) - Trifacta, the global leader in data wrangling, today announced the release of Trifacta v4. The latest release expands upon Trifacta's award-winning...
September 20, 2016 08:44 ET | Source: Zealand Pharma

Zealand-sponsoreret uddannelsessymposium understreger behovet for bedre medicinsk behandling af korttarmssyndrom

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Pressemeddelelse - Nr. 5 / 2016 ...
September 20, 2016 08:44 ET | Source: Zealand Pharma

Zealand sponsored educational symposium highlights the need for better medical treatment of short bowel syndrome

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Press release - No. 5 / 2016 Zealand...
September 19, 2016 04:44 ET | Source: Research and Markets

Global Antithrombotic/Anticoagulant Drugs Market To Reach $27.3 Billion by 2021 From $18.9 Billion in 2016 - Global Analysis Report

Dublin, Sept. 19, 2016 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Antithrombotic/Anticoagulant Drugs - Technologies and Global Markets" report to...
September 19, 2016 01:00 ET | Source: Sanofi Winthrop Industrie

Sanofi intente une action en justice aux Etats-Unis pour défendre les brevets de Lantus® et Lantus® Solostar®

Sanofi intente une action en justice aux Etats-Unis pour défendre les brevets de Lantus® et Lantus® Solostar® Paris, France - Le 19 septembre 2016 - Sanofi annonce aujourd'hui avoir intenté le...
September 19, 2016 01:00 ET | Source: Sanofi Winthrop Industrie

Sanofi Files Suit in U.S. to Defend Paten Rights on Lantus® and Lantus® Solostar®

Sanofi Files Suit in U.S. to Defend Patent Rights on Lantus® and Lantus® Solostar® Paris, France - September 19, 2016 - Sanofi announced today that it filed a patent infringement suit against...
September 16, 2016 10:30 ET | Source: Sanofi Winthrop Industrie

Sanofi : Maintien des effets thérapeutiques de Lemtrada® (alemtuzumab) de Genzyme pendant six ans pour la majorité des patients atteints de formes rémittentes de sclérose en plaques traités au cour...

Maintien des effets thérapeutiques de Lemtrada® (alemtuzumab) de Genzyme pendant six ans pour la majorité des patients atteints de formes rémittentes de sclérose en plaques traités au cours d'essais...
September 16, 2016 10:30 ET | Source: Sanofi Winthrop Industrie

Sanofi: Treatment Effects Maintained Over Six Years in Patients with Relapsing Remitting Multiple Sclerosis who Received Sanofi Genzyme's Lemtrada® (alemtuzumab) in Clinical Trials

Treatment Effects Maintained Over Six Years in Patients with Relapsing Remitting Multiple Sclerosis who Received Sanofi Genzyme's Lemtrada® (alemtuzumab) in Clinical Trials - At six years in the...
September 15, 2016 08:00 ET | Source: Sanofi Winthrop Industrie

Sanofi : Informations relatives au nombre total de droits de vote et d'actions prévues par l'article L. 233-8 II du Code de commerce et l'article 223-16 du Règlement général de l'Autorité des March...

Informations relatives au nombre total de droits de vote et d'actions prévues par l'article L. 233-8 II du Code de commerce et l'article 223-16 du Règlement général de l'Autorité des Marchés...
September 15, 2016 08:00 ET | Source: Sanofi Winthrop Industrie

Sanofi: Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the ...

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the...